Diabetes is common in hospitalised patients and insulin is frequently required for management. Insulin is a high-risk drug, accounting for about 15% of reported medication-related incidents. Despite its complexity, insulin management in hospitals is often undertaken by junior and nonspecialist staff. Improving insulin management requires addressing safe prescribing and administration as well as quality use of insulin. Common errors in insulin use are well documented and can be addressed through form design and enhancing decision support. We undertook to improve insulin management using a locally proven improvement methodology. New forms were developed for intravenous and subcutaneous insulin and blood glucose management. Audited pilot studies in four hospitals confirmed improved insulin management without adversely impacting on overall diabetes management as assessed using Glucometrics. Subsequently, the forms have been introduced to 70% of Queensland public hospitals with roll-out to remaining hospitals continuing. Large-scale standardisation of insulin manage- INSULIN IS RECOGNISED internationally as a highrisk drug, accounting for about 15% of the highest risk actual and potential medicationrelated incidents.
INSULIN IS RECOGNISED internationally as a highrisk drug, accounting for about 15% of the highest risk actual and potential medicationrelated incidents. 1 Errors in insulin prescribing and administration often occur as a result of unclear documentation, as well as the need to review multiple documents. 2 In addition to errors, the quality of insulin management is often suboptimal due to junior and non-specialist clinicians' limited knowledge of: ■ the many insulin types and brands and their pharmacological properties; ■ insulin dosing and blood glucose level (BGL) management; and ■ the complexity of tailoring a patient' s dosing regimen to their individual requirements. This has led to inappropriate or a lack of appropriate responses to BGLs that are outside the limits set for notification of hyperglycaemia and hypoglycaemia.
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What is known about the topic? Recent literature has seen an increased focus on inpatient diabetes management, with studies demonstrating that glycaemic control is poor. Tools and protocols that have been implemented to standardise treatment have largely been unit or hospital based.
What does this paper add?
This paper demonstrates that large scale, state-wide standardisation of prescribing tools incorporating features to aid safe prescribing can be achieved without adversely affecting blood glucose control.
What are the implications for practitioners?
Reduced training costs in a highly mobile health workforce and minimisation of unclear prescribing through the use of incorporated safety features are potential benefits of standardised prescribing forms for diabetes management. However, such tools cannot be expected to improve blood glucose control without extensive educational intervention.
Quality and Safety Interventions
Standardised inpatient diabetes management has not previously been systematically addressed across a statewide hospital system. Suboptimal treatment methods, including a lack of proactive management of hyperglycaemia, are well documented. 3 There has been a recent increase in focus on inpatient management of glycaemia internationally. 4 Improved glycaemic control has recently been demonstrated by the use of "proactive" intensive insulin therapy (basal insulin in combination with premeal routine and supplemental rapid-acting insulin) in comparison with stand-alone "reactive" subcutaneous insulin "sliding scales" (using variable doses of rapid-acting insulin according to the blood glucose level at time of administration). 5 Ausdiab 2001 6 estimated the prevalence of diabetes in the Australian adult population at 7.5%. The prevalence of diabetes in Australian tertiary hospital patients has been estimated at 23%. 7 Considering that diabetes in hospitalised patients is common and insulin is frequently prescribed, there is a need to ensure the safe and effective prescribing, administering and monitoring of medications for diabetes, particularly of insulin.
The reported incidence of actual harm occurring as a result of insulin errors is quite low. However, insulin errors have resulted in death and severe morbidity. Hellman 8 found that 33% of medication error-related deaths that occurred within 48 hours of the error were attributable to insulin. The incidence and probable causes need to be reported together with "near misses" so that solutions can be found to reducing the likelihood of harm. 9 Distinctions need to be made between safe prescribing of insulin, its safe administration and quality management of BGLs.
Our group addressed the recognised issues of suboptimal insulin prescribing and administra- Quality and Safety Interventions tion separately as the first step in improving overall insulin management.
Form redesign was undertaken to improve the safety of insulin prescribing and administration. This enables: ■ all documentation required to prescribe and administer insulin being on one form; ■ the inclusion of prompts for clinicians, and features that will reduce or eliminate the use of unsafe documentation. For example, eliminating the use of "u" as an abbreviation for "units" was expected to facilitate this. Additionally, prompts have been incorporated to encourage the use of intensive insulin regimens in place of sliding scales. Standardisation and the resultant uniformity of practice have been shown locally to reduce prescribing and administration errors, 10 and a pilot study involving insulin administration resulted in a reduction of the frequency of hypoglycaemia.
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The primary aim of this medication initiative was to improve the safety of insulin prescribing and administration in Queensland public hospitals without adversely affecting blood glucose control. Common errors related to insulin that have previously been documented are listed in Box 1. This study was undertaken to measure the effect of the form redesign and system change introduced, through the use of standardised preand post-implementation audit of processes that are identified factors in insulin safety (Box 2). Glucometrics 13 assessment was also undertaken to determine impact on glucose control, an outcome measure.
Methods

System change
A locally proven methodology was used. 10 A statewide expert panel, including endocrinologists, advanced trainees, pharmacists, physicians, diabetes educators and medication safety nurses, was engaged to design prescribing and administration forms for insulin. Two forms were designed, one for intravenous insulin and one for subcutaneous insulin, with BGL monitoring incorporated into both forms (see pages 442 and 443). Safety features and enabling functions were incorporated into the forms and are listed in Box 2. Consensus and available evidence guided the development. Throughout the iterative process, the forms were assessed using prescribing and administration scenarios on medical students and clinical staff, with varying experience and expertise in diabetes management. Staff involved included interns, junior house officers and registrars, pharmacists, nursing staff from medical and surgical wards and diabetes educators. The assessments were carried out before piloting the forms and when significant format changes were applied.
A decision support tool for the management of hypoglycaemia was developed and incorporated (see page 444). The form also incorporated
Safety features
Subcutaneous insulin prescribing and administration form Intravenous insulin infusion ordering and administration form
Route of administration clearly identified
Route of administration clearly identified Notification prompts for blood glucose levels outside target range
Notification prompts for blood glucose levels outside target range "Units" pre-printed "Units" pre-printed 
Measuring the effect of system change
The complex nature of insulin management has led to difficulties in determining appropriate measures to evaluate the effectiveness of the system change. In view of this, two audits were undertaken before implementation of the new forms. ■ Documentation audit, measuring:
➤ type of insulin regimen prescribed; ➤ clarity of insulin prescribing and potential opportunities for error as a result of unclear prescribing; ➤ clarity and correctness of documentation of administration of ordered insulin doses; and ➤ documentation of treatment in response to hypoglycaemic and hyperglycaemic episodes. ■ Blood glucose control audit, using Glucometrics, 13 in which:
➤ the date and time of BGLs were collected retrospectively. BGLs on the day of admission were excluded. ➤ there was no minimum timeframe for recording BGLs for intravenous insulin, with a maximum of 72 hours, at any time during the admission. ➤ BGLs from a minimum of 48 hours and a maximum of 72 hours duration within the first 4 days of the admission were recorded for subcutaneous insulin-and non-insulintreated streams; ➤ The BGL data were separated into treatment streams of intravenous or subcutaneous insulin-and non-insulin-treated BGL monitoring. The data were entered into a spreadsheet and converted to milligrams per decilitre using a conversion factor of 18 and then uploaded following the required formatting to the Medical Informatics page of the Yale School of Medicine website. The report provided by the Yale website included both percentage of mean BGLs over inpatient days in range, and percentage of patient days where there was any hypoglycaemic (BGL < 3.9 mmol/L) event or any hyperglycaemic event (BGL > 16.6 mmol/L). The audits were repeated at the same hospitals 3 months after the implementation.
Data collection
Data were collected at four Queensland Health tertiary and regional hospitals using a convenience sample. There were 117 patients in the preimplementation audit and 82 patients in the postimplementation audit. All wards were included in each hospital except paediatrics, mental health and intensive care units. Audits were undertaken on separate days in each ward within a 1-week period. Data on intravenous and subcutaneous treatment streams were collected independently and a single patient could contribute to both collections. However, no patient had their data collected twice by virtue of a change in ward during the audit period.
The data from all patients having BGLs recorded who met the above criteria were included.
Analysis
Pre-and post-implementation data were analysed using χ 2 to test for significance of difference between two independent proportions. When χ 2 assumptions were not met, Fisher' s Exact Test was used. The tests for the alternative hypotheses were two-tailed. Probability was set at P < 0.05.
Results
The results are displayed in Boxes 3 to 7 with proportions pre and post implementation of the Intravenous and Subcutaneous Insulin Prescribing and Administration forms. Box 3 lists the type of subcutaneous insulin treatment used in the study. Box 4 and Box 5 report the results of the intravenous documentation audit and the subcu-Quality and Safety Interventions taneous documentation audit respectively. Responses to hypoglycaemic and hyperglycaemic episodes are displayed in Box 6. Finally, blood glucose control, pre and post implementation, as measured by Glucometrics is shown in Box 7.
Discussion
An absolute difference of 24.2% in the post compared with the pre audit for the use of supplemental insulin was significant (Fisher' s Exact Test, P = 0.002). The use of supplemental insulin at higher
Subcutaneous insulin documentation audit results
Criteria
Pre (%)* Post (%)* P (two-tailed)
Subcutaneous insulin prescribing
Opportunity for administration error as Quality and Safety Interventions rates is encouraged as part of the intensive treatment for improved glycaemic control in hospitalised patients with hyperglycaemia. 4 The following significant improvements were demonstrated in several aspects of insulin prescribing and administration following the implementation of both the Intravenous and Subcutaneous forms.
Intravenous insulin documentation audit results
Criteria
Quality and Safety Interventions
➤ prevent or minimise the use of non-standard abbreviations (P < 0.0002); ➤ clearly indicate the frequency (timing) of the insulin dose by associating it with a meal (P < 0.0002); ➤ clearly indicate the intended route of administration (P < 0.0002). ■ Improvement in the clarity of administered insulin doses (P = 0.0014).
The notification of hypoglycaemia to a medical officer was also significantly improved. The documentation of appropriate management of hypoglycaemia incorporating repeated BGLs at 15 minutes and 60 minutes did not reach statistical significance, but the sample sizes were small. Hyperglycaemia notification did not improve, highlighting that alert criteria are necessary but not sufficient. To address this, the most recent iterations of the forms include decision support so that nursing staff have a clear indication of the response to expect and medical staff are guided in managing such alerts.
There was a clinically important reduction in hypoglycaemia with the use of the intravenous insulin form. While there was no improvement in other Glucometrics results, this was not the aim of the intervention and these results demonstrate that improvements in the safety of insulin prescribing and administration can be achieved without deterioration in BGL control. Decision support for medical officers to follow in the event of a high or low BGL notification was not included in this iteration of the form. The form has now been modified to incorporate prescribing decision support.
Glucometrics allowed robust assessment of improvements in glucose control. Improvements in other aspects of insulin administration documentation were harder to ascertain, as documentation in use before the introduction of the new forms did not allow determination of whether the dose had been calculated correctly.
Both forms have subsequently been introduced to about 70% of public hospital beds in Queensland. Therefore, we are now in a position to promote the forms to medical, nursing and pharmacy schools in Queensland such that they can ensure that their graduates are familiar with the forms' features and gain practical experience in their use before graduation.
Limitations
Consistent with the pragmatic approach to development and introduction of the new forms, this was not a randomised trial. No adjustments were made for possible differences in clinical, staffing or other resource factors. Data from all hospitals were pooled and between-hospital differences were not assessed. Observation bias could also have occurred, although the impact of this is unlikely to have been significant as insulin prescribing and administration were undertaken by many clinical staff and the audit periods were not advised in advance. Follow-up data at 12 months will be collected to determine sustainability of the changes.
Conclusion
This study demonstrates that improvements in insulin prescribing, documentation of administration and some important aspects of insulin and blood glucose management can be achieved through form design and structured implementation packages. To our knowledge, this is the first report of standardisation of insulin management and forms across a statewide public hospital system. The results demonstrate that large scale clinical standardisation projects can be successful.
Further work is required to address the quality management of diabetes and insulin. It is expected that this will require improved decision support introduced with change management support and attention to workplace issues, including resources, longstanding work practices and culture.
Audits including the use of Glucometrics will enable us to evaluate whether or not the subsequent interventions have resulted in further improvements in management.
